The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Site Search
The Cystic Fibrosis Foundation joins 15 patient and provider groups to oppose this bill, which would negatively impact patients' access to adequate and affordable health coverage and care.
A nonpartisan group of 29 patient, provider, and consumer groups praised the Senate Health, Education, Labor, and Pensions (HELP) Committee for crafting bipartisan legislation that will help stabilize the individual insurance markets.
Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
New Agreement Increases Potential Payments to EPIX by up to $37.7 Million